Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease: Newer data

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Mavrogiannaki, A N ^a   Migdalis, I N ^a  

^a NIMTS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ANTILIPEMIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; MALONALDEHYDE; METFORMIN; RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ARTERY INTIMA PROLIFERATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; DIAGNOSTIC IMAGING; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SURVEILLANCE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSLIPIDEMIA; EARLY DIAGNOSIS; EXERCISE; FIBROGENESIS; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOTOXICITY; LIVER BIOPSY; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; WEIGHT REDUCTION;

EID: 84877247095     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/450639     Document Type: Review

References (73)

1. Gholam P. M., Kotler D. P., Flancbaum L. J., Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obesity Surgery 2002 12 1 49 51 2-s2.0-0036180253 10.1381/096089202321144577 (Pubitemid 34155261)
2. Williams C. D., Stengel J., Asike M. I., Torres D. M., Shaw J., Contreras M., Landt C. L., Harrison S. A., Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011 140 1 124 131 2-s2.0-78650486196 10.1053/j.gastro.2010.09.038
3. Targher G., Bertolini L., Padovani R., Rodella S., Zoppini G., Pichiri I., Sorgato C., Zenari L., Bonora E., Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. Journal of Hepatology 2010 53 4 713 718 2-s2.0-77956266803 10.1016/j.jhep.2010.04.030
4. Caserta C. A., Pendino G. M., Amante A., Vacalebre C., Fiorillo M. T., Surace P., Messineo A., Surace M., Alicante S., Cotichini R., Zuin M., Rosmini F., Mele A., Marcucci F., Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. The American Journal of Epidemiology 2010 171 11 1195 1202 2-s2.0-77952921855 10.1093/aje/kwq073
5. Browning J. D., Statins and hepatic steatosis: perspectives from the Dallas heart study. Hepatology 2006 44 2 466 471 2-s2.0-33747047274 10.1002/hep.21248 (Pubitemid 44214886)
6. Malhi H., Gores G. J., Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Seminars in Liver Disease 2008 28 4 360 369 2-s2.0-56649094325 10.1055/s-0028-1091980
7. Targher G., Day C. P., Bonora E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. The New England Journal of Medicine 2010 363 14 1341 1350 2-s2.0-77957375969 10.1056/NEJMra0912063
8. Targher G., Marra F., Marchesini G., Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008 51 11 1947 1953 2-s2.0-53549112749 10.1007/s00125-008-1135-4
9. Baumeister S. E., Völzke H., Marschall P., John U., Schmidt C. O., Flessa S., Alte D., Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008 134 1 85 94 2-s2.0-37349053742 10.1053/j.gastro.2007.10.024 (Pubitemid 350309322)
10. Leite N. C., Salles G. F., Araujo A. L. E., Villela-Nogueira C. A., Cardoso C. R. L., Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver International 2009 29 1 113 119 2-s2.0-57749183469 10.1111/j.1478-3231.2008.01718.x
11. Kotronen A., Juurinen L., Hakkarainen A., Westerbacka J., Cornér A., Bergholm R., Yki-Järvinen H., Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008 31 1 165 169 2-s2.0-38149030206 10.2337/dc07-1463
12. Speliotes E. K., Massaro J. M., Hoffmann U., Vasan R. S., Meigs J. B., Sahani D. V., Hirschhorn J. N., O'Donnell C. J., Fox C. S., Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham heart study. Hepatology 2010 51 6 1979 1987 2-s2.0-77952680758 10.1002/hep.23593
13. Fracanzani A. L., Valenti L., Bugianesi E., Andreoletti M., Colli A., Vanni E., Bertelli C., Fatta E., Bignamini D., Marchesini G., Fargion S., Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008 48 3 792 798 2-s2.0-51349083814 10.1002/hep.22429
14. Harrison S. A., Oliver D., Arnold H. L., Gogia S., Neuschwander-Tetri B. A., Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008 57 10 1441 1447 2-s2.0-52649112178 10.1136/gut.2007.146019
15. Cusi K., The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Current Diabetes Reports 2010 10 4 306 315 2-s2.0-77956395533 10.1007/s11892-010-0122-6
16. Kotronen A., Yki-Järvinen H., Fatty liver: a novel component of the metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 1 27 38 10.1161/ATVBAHA.107.147538
17. Sattar N., McConnachie A., Ford I., Gaw A., Cleland S. J., Forouhi N. G., McFarlane P., Shepherd J., Cobbe S., Packard C., Serial metabolic measurements and conversion to type 2 diabetes in the West of Scotland Coronary Prevention Study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 2007 56 4 984 991 2-s2.0-34047098736 10.2337/db06-1256 (Pubitemid 46525076)
18. Schindhelm R. K., Dekker J. M., Nijpels G., Bouter L. M., Stehouwer C. D. A., Heine R. J., Diamant M., Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007 191 2 391 396 2-s2.0-33947169979 10.1016/j.atherosclerosis.2006.04.006 (Pubitemid 46400701)
19. Hamaguchi M., Takeda N., Nagata C., Takeda J., Sarui H., Kawahito Y., Yoshida N., Suetsugu A., Kato T., Okuda J., Ida K., Yoshikawa T., Nonalcolholic fatty liver disease is a novel predictor cardiovascular disease. World Journal of Gastroenterology 2007 13 10 1579 1584 (Pubitemid 46672668)
20. Ioannou G. N., Weiss N. S., Boyko E. J., Mozaffarian D., Lee S. P., Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006 43 5 1145 1151 2-s2.0-33646547644 10.1002/hep.21171 (Pubitemid 43724639)
21. Ekstedt M., Franzén L. E., Mathiesen U. L., Thorelius L., Holmqvist M., Bodemar G., Kechagias S., Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006 44 4 865 873 2-s2.0-33750606061 10.1002/hep.21327 (Pubitemid 46489550)
22. Treeprasertsuk S., Lopez-Jimenez F., Lindor K. D., Nonalcoholic fatty liver disease and the coronary artery disease. Digestive Diseases and Sciences 2011 56 1 35 45 2-s2.0-79151478841 10.1007/s10620-010-1241-2
23. Targher G., Bertolini L., Padovani R., Rodella S., Zoppini G., Zenari L., Cigolini M., Falezza G., Arcaro G., Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006 29 6 1325 1330 2-s2.0-33746421488 10.2337/dc06-0135 (Pubitemid 44125930)
24. Villanova N., Moscatiello S., Ramilli S., Bugianesi E., Magalotti D., Vanni E., Zoli M., Marchesini G., Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005 42 2 473 480 2-s2.0-23044512117 10.1002/hep.20781 (Pubitemid 41061101)
25. Targher G., Bertolini L., Rodella S., Lippi G., Franchini M., Zoppini G., Muggeo M., Day C. P., NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity 2008 16 6 1394 1399 2-s2.0-44449109670 10.1038/oby.2008.64 (Pubitemid 351770539)
26. Donati G., Stagni B., Piscaglia F., Venturoli N., Morselli-Labate A. M., Rasciti L., Bolondi L., Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004 53 7 1020 1023 2-s2.0-3042521502 10.1136/gut.2003.027086 (Pubitemid 38824162)
27. Perseghin G., Lattuada G., De Cobelli F., Esposito A., Belloni E., Ntali G., Ragogna F., Canu T., Scifo P., Del Maschio A., Luzi L., Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008 47 1 51 58 2-s2.0-38649091680 10.1002/hep.21983 (Pubitemid 351171041)
28. Zib I., Jacob A. N., Lingvay I., Salinas K., McGavock J. M., Raskin P., Szczepaniak L. S., Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. Journal of Investigative Medicine 2007 55 5 230 236 2-s2.0-35048878739 10.2310/6650.2007. 00003 (Pubitemid 47555941)
29. Targher G., Bertolini L., Poli F., Rodella S., Scala L., Tessari R., Zenari L., Falezza G., Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005 54 12 3541 3546 2-s2.0-33644700376 10.2337/diabetes.54.12.3541 (Pubitemid 43334347)
30. Targher G., Bertolini L., Rodella S., Tessari R., Zenari L., Lippi G., Arcaro G., Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007 30 8 2119 2121 2-s2.0-34547673500 10.2337/dc07-0349 (Pubitemid 47219432)
31. Cusi K., Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity 2009 16 2 141 149 2-s2.0-66149088144 10.1097/MED.0b013e3283293015
32. Angulo P., Medical progress: nonalcoholic fatty liver disease. The New England Journal of Medicine 2002 346 16 1221 1231 2-s2.0-0037129380 10.1056/NEJMra011775 (Pubitemid 34984585)
33. Day C. P., Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005 129 1 375 378 2-s2.0-22344453700 10.1053/j.gastro.2005.05.041 (Pubitemid 41002070)
34. Petersen K. F., Dufour S., Hariri A., Nelson-Williams C., Foo J. N., Zhang X. M., Dziura J., Lifton R. P., Shulman G. I., Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. The New England Journal of Medicine 2010 362 12 1082 1089 2-s2.0-77950202777 10.1056/NEJMoa0907295
35. de Alwis N. M. W., Day C. P., Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Seminars in Liver Disease 2007 27 1 44 54 2-s2.0-33847008303 10.1055/s-2006-960170
36. de Alwis N. M. W., Day C. P., Genes and nonalcoholic fatty liver disease. Current Diabetes Reports 2008 8 2 156 163 2-s2.0-44849125451 10.1007/s11892-008-0027-9
37. Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., Fagà E., Silli B., Pagano G., Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003 37 4 909 916 2-s2.0-0037382071 10.1053/jhep.2003.50132 (Pubitemid 36397404)
38. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Blendis L., Halpern Z., Oren R., Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. Journal of Hepatology 2007 47 5 711 717 2-s2.0-34848830434 10.1016/j.jhep.2007.06.020 (Pubitemid 47503432)
39. Chalasani N., Younossi Z., Lavine J. E., Diehl A. M., Brunt E. M., Cusi K., Charlton M., Sanyal A. J., The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. The American Journal of Gastroenterology 2012 107 6 811 826 10.1038/ajg.2012.128
40. Taouli B., Ehman R. L., Reeder S. B., Advanced MRI methods for assessment of chronic liver disease. The American Journal of Roentgenology 2009 193 1 14 27 2-s2.0-67650287923 10.2214/AJR.09.2601
41. Wieckowska A., McCullough A. J., Feldstein A. E., Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007 46 2 582 589 2-s2.0-34548306754 10.1002/hep.21768 (Pubitemid 47344794)
42. Solga S. F., Alkhuraishe A., Cope K., Tabesh A., Clark J. M., Torbenson M., Schwartz P., Magnuson T., Diehl A. M., Risby T. H., Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations. Biomarkers 2006 11 2 174 183 2-s2.0-33646831000 10.1080/13547500500421070 (Pubitemid 43772014)
43. Kalhan S. C., Guo L., Edmison J., Dasarathy S., McCullough A. J., Hanson R. W., Milburn M., Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011 60 3 404 413 2-s2.0-79951792246 10.1016/j.metabol.2010. 03.006
44. Angulo P., Hui J. M., Marchesini G., Bugianesi E., George J., Farrell G. C., Enders F., Saksena S., Burt A. D., Bida J. P., Lindor K., Sanderson S. O., Lenzi M., Adams L. A., Kench J., Therneau T. M., Day C. P., The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007 45 4 846 854 2-s2.0-34247384560 10.1002/hep.21496 (Pubitemid 46631552)
45. Ueno T., Sugawara H., Sujaku K., Hashimoto O., Tsuji R., Tamaki S., Torimura T., Inuzuka S., Sata M., Tanikawa K., Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. Journal of Hepatology 1997 27 1 103 107 2-s2.0-0030740659 10.1016/S0168-8278(97)80287-5 (Pubitemid 27357062)
46. Promrat K., Kleiner D. E., Niemeier H. M., Jackvony E., Kearns M., Wands J. R., Fava J. L., Wing R. R., Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010 51 1 121 129 2-s2.0-73449116035 10.1002/hep.23276
47. Luyckx F. H., Desaive C., Thiry A., Dewé W., Scheen A. J., Gielen J. E., Lefèbvrc P. J., Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. International Journal of Obesity 1998 22 3 222 226 2-s2.0-0031913573 (Pubitemid 28112021)
48. Harrison S. A., Fecht W., Brunt E. M., Neuschwander-Tetri B. A., Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009 49 1 80 86 2-s2.0-58949102847 10.1002/hep.22575
49. van Werven J. R., Schreuder T. C. M. A., Aarts E. O., Nederveen A. J., Meijer J. W. R., Berends F. J., Janssen I. M. C., Mulder C. J., Jansen P. L. M., Stoker J., Hepatic steatosis in morbidly obese patients undergoing gastric bypass surgery: assessment with open-system 1H-MR spectroscopy. The American Journal of Roentgenology 2011 196 6 W736 W742 10.2214/AJR.10.5215
50. Sjöström L., Narbro K., Sjöström C. D., Karason K., Larsson B., Wedel H., Lystig T., Sullivan M., Bouchard C., Carlsson B., Bengtsson C., Dahlgren S., Gummesson A., Jacobson P., Karlsson J., Lindroos A. K., Lönroth H., Näslund I., Olbers T., Stenlöf K., Torgerson J., Ågren G., Carlsson L. M. S., Effects of bariatric surgery on mortality in Swedish obese subjects. The New England Journal of Medicine 2007 357 8 741 752 2-s2.0-34548090763 10.1056/NEJMoa066254 (Pubitemid 47295641)
51. Krasnoff J. B., Painter P. L., Wallace J. P., Bass N. M., Merriman R. B., Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2008 47 4 1158 1165 2-s2.0-42249114813 10.1002/hep.22137 (Pubitemid 351547902)
52. Johnson N. A., Sachinwalla T., Walton D. W., Smith K., Armstrong A., Thompson M. W., George J., Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009 50 4 1105 1112 2-s2.0-70350072281 10.1002/hep.23129
53. Leuschner U. F. H., Lindenthal B., Herrmann G., Arnold J. C., Rössle M., Cordes H. J., Zeuzem S., Hein J., Berg T., Löhr H., Möller B., Pape S., Vafiadi-Zoubouli I., Tsianos E., Grüngreiff K., Kouroumalis E., Pirlich M., Menges M., Hüppe D., Teubner K. M., Preiss J., Holstege A., Lutz M., Dieekmann L. T., Goerg K. J., Swobodnik W., High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010 52 2 472 479 2-s2.0-77955699301 10.1002/hep.23727
54. Chae M. K., Park S. G., Song S.-O., Kang E. S., Cha B. S., Lee H. C., Lee B.-W., Pentoxifylline attenuates methionine- and choline-deficient-diet-induced steatohepatitis by suppressing TNF- α expression and endoplasmic reticulum stress. Experimental Diabetes Research 2012 2012 8 762565 10.1155/2012/762565
55. Adams L. A., Zein C. O., Angulo P., Lindor K. D., A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. The American Journal of Gastroenterology 2004 99 12 2365 2368 2-s2.0-11144249271 10.1111/j.1572-0241. 2004.40064.x (Pubitemid 40039367)
56. Sanyal A. J., Chalasani N., Kowdley K. V., McCullough A., Diehl A. M., Bass N. M., Neuschwander-Tetri B. A., Lavine J. E., Tonascia J., Unalp A., Van Natta M., Clark J., Brunt E. M., Kleiner D. E., Hoofnagle J. H., Robuck P. R., Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England Journal of Medicine 2010 362 18 1675 1685 2-s2.0-77951874018 10.1056/NEJMoa0907929
57. Nobili V., Manco M., Devito R., Di Ciommo V., Comparcola D., Sartorelli M. R., Piemonte F., Marcellini M., Angulo P., Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008 48 1 119 128 2-s2.0-47149086771 10.1002/hep.22336 (Pubitemid 351975537)
58. Lavine J. E., Schwimmer J. B., Van Natta M. L., Molleston J. P., Murray K. F., Rosenthal P., Abrams S. H., Scheimann A. O., Sanyal A. J., Chalasani N., Tonascia J., nalp A., Clark J. M., Brunt E. M., Kleiner D. E., Hoofnagle J. H., Robuck P. R., Nonalcoholic steatohepatitis clinical research network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. Journal of the American Medical Association 2011 305 16 1659 1668
59. Hirose A., Ono M., Saibara T., Nozaki Y., Masuda K., Yoshioka A., Takahashi M., Akisawa N., Iwasaki S., Oben J. A., Onishi S., Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007 45 6 1375 1381 2-s2.0-34250323865 10.1002/hep.21638 (Pubitemid 46918321)
60. Riley P., Sudarshi D., Johal M., Benedict A., Panteli J., Crook M., O'Donohue J., Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. International Journal of Clinical Practice 2008 62 3 374 381 2-s2.0-38849148319 10.1111/j.1742-1241.2007.01666.x (Pubitemid 351197418)
61. Park H., Shima T., Yamaguchi K., Mitsuyoshi H., Minami M., Yasui K., Itoh Y., Yoshikawa T., Fukui M., Hasegawa G., Nakamura N., Ohta M., Obayashi H., Okanoue T., Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. Journal of Gastroenterology 2011 46 1 101 117 2-s2.0-78651473467 10.1007/s00535-010-0291-8
62. Filippatos T. D., Elisaf M. S., Combination drug treatment in patients with non-alcoholic fatty liver disease. World Journal of Hepatology 2010 2 4 139 142
63. Vega G. L., Chandalia M., Szczepaniak L. S., Grundy S. M., Effects of N-3 fatty acids on hepatic triglyceride content in humans. Journal of Investigative Medicine 2008 56 5 780 785 2-s2.0-49149084590
64. Juurinen L., Tiikkainen M., Häkkinen A. M., Hakkarainen A., Yki-Järvinen H., Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. The American Journal of Physiology 2007 292 3 E829 E835 2-s2.0-33947131149 10.1152/ajpendo.00133.2006 (Pubitemid 46411061)
65. Gupta N. A., Mells J., Dunham R. M., Grakoui A., Handy J., Saxena N. K., Anania F. A., Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010 51 5 1584 1592 2-s2.0-77951436599 10.1002/hep.23569
66. Samson S. L., Bajaj M., Potential of incretin-based therapies for non-alcoholic fatty liver disease. Journal of Diabetes and Its Complications 201310.1016/j.jdiacomp.2012.12.005
67. Athyros V. G., Giouleme O., Ganotakis E. S., Elisaf M., Tziomalos K., Vassiliadis T., Liberopoulos E. N., Theocharidou E., Karagiannis A., Mikhailidis D. P., Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Archives of Medical Science 2011 7 5 796 805 10.5114/aoms.2011.25554
68. American Diabetes Association, Clinical practice recommendations. Diabetes Care 2013 26 Suppl 1 S11 S67
69. Fassio E., Álvarez E., Domínguez N., Landeira G., Longo C., Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004 40 4 820 826 2-s2.0-4644297019 10.1002/hep.20410 (Pubitemid 39288114)
70. Dixon J. B., Bhathal P. S., O'Brien P. E., Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001 121 1 91 100 2-s2.0-0034950652 (Pubitemid 32591518)
71. White D. L., Kanwal F., El-Serag H. B., Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clinical Gastroenterology and Hepatology 2012 10 12 1342 1359 10.1016/j.cgh.2012.10.001
72. Söderberg C., Stål P., Askling J., Glaumann H., Lindberg G., Marmur J., Hultcrantz R., Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010 51 2 595 602 2-s2.0-75449088414 10.1002/hep.23314
73. Adams L. A., Harmsen S., Sauver J. L. S., Charatcharoenwitthaya P., Enders F. B., Therneau T., Angulo P., Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. The American Journal of Gastroenterology 2010 105 7 1567 1573 2-s2.0-77954424925 10.1038/ajg.2010.18